Effect of nirmatrelvir/ritonavir (Paxlovid) on hospitalization among adults with COVID-19: An electronic health record-based target trial emulation from N3C.
<h4>Background</h4>Nirmatrelvir with ritonavir (Paxlovid) is indicated for patients with Coronavirus Disease 2019 (COVID-19) who are at risk for progression to severe disease due to the presence of one or more risk factors. Millions of treatment courses have been prescribed in the United...
Saved in:
Main Authors: | Abhishek Bhatia, Alexander J Preiss, Xuya Xiao, M Daniel Brannock, G Caleb Alexander, Robert F Chew, Hannah Davis, Megan Fitzgerald, Elaine Hill, Elizabeth P Kelly, Hemalkumar B Mehta, Charisse Madlock-Brown, Kenneth J Wilkins, Christopher G Chute, Melissa Haendel, Richard Moffitt, Emily R Pfaff, N3C Consortium |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2025-01-01
|
Series: | PLoS Medicine |
Online Access: | https://doi.org/10.1371/journal.pmed.1004493 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Real‐world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (Paxlovid) in hospitalized patients with COVID-19: a multicenter, retrospective, cohort study
by: Haiyu Wang, et al.
Published: (2025-01-01) -
Data mining of adverse drug event signals with Nirmatrelvir/Ritonavir from FAERS.
by: Ji Sun, et al.
Published: (2024-01-01) -
Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series
by: Alison K. Cohen, et al.
Published: (2025-01-01) -
Real-world effectiveness of azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 and pre-existing diabetes
by: Guanyue Su, et al.
Published: (2025-02-01) -
The interaction between nirmatrelvir/ritonavir and sirolimus: a case report of a kidney recipient with renal insufficiency and COVID-19
by: Yinhua Gong, et al.
Published: (2025-01-01)